An evaluation of a new Afinion AS100 Analyzer was conducted to assess analytical performance. Precision was estimated by analyzing 2 control and 3 patient samples twice a day for 10 days. Accuracy was established by analysis of 6 samples from the National Glycated Hemoglobin Standardization Program for a 3-day period. Agreement was correlated to a laboratory method, the Variant II Turbo Hemoglobin Testing System, and a point-of-care method, the DCA2000+ Hemoglobin A1cSystem, using leftover EDTA samples from laboratory analysis (n = 110, range of results = 4.6%-13.7% HbA1c). The Afinion AS100 Analyzer (0.9%-1.8% coefficient of variation CV) displayed laboratory comparable precision (Variant II Turbo = 1.1%-1.9% CV) that was superior to the DCA2000+ (2.9%-3.3% CV) with minimal bias to the National Glycated Hemoglobin Standardization Program target concentrations (<0.2% HbA1caverage unit bias or 3.1%). The Afinion AS100 Analyzer had good agreement with both the Variant II Turbo and DCA2000+ with rof greater than 0.9837 and Sy.x of ±0.22% and ±0.29% HbA1c, respectively. Staff found the analyzer easy to train and use, providing faster results than the DCA2000+ (3 minutes vs 6 minutes). The Afinion AS100 Analyzer will be recommended over the DCA2000+ when requests for future point-of-care HbA1care made in our health system.